Table 4. Number of patients with serious adverse events during follow-up at day 90 classified by local investigators and central adjudicators: GTN vs no GTN and continue vs stop.

	GTN (n = 2000)	No GTN (n = 2011)	p-value*	Continue (n = 1053)	Stop (n = 1044)	p-value*
Any SAE
Local Investigator	522	509	0.57	312	297	0.55
Central Adjudicator	520	502	0.45	310	294	0.52
Complication of initial stroke
Local Investigator	67	53	0.18	26	36	0.19
Central Adjudicator	40	31	0.27	19	16	0.63
Extension of initial stroke
Local Investigator	50	37	0.15	32	23	0.23
Central Adjudicator	59	37	0.021	33	23	0.19
Symptomatic intracranial haemorrhage
Local Investigator	23	19	0.52	10	18	0.12
Central Adjudicator	27	17	0.13	11	16	0.32
Recurrent stroke
Local Investigator	57	32	0.007	29	27	0.81
Central Adjudicator	47	35	0.17	25	27	0.80
Myocardial infarction
Local Investigator	18	25	0.29	9	18	0.077
Central Adjudicator	19	22	0.65	11	16	0.32
Sudden cardiac death
Local Investigator	3	5	0.48	1	3	0.31
Central Adjudicator	6	6	0.99	1	5	0.10
Other cardiovascular event
Local Investigator	119	103	0.25	64	72	0.45
Central Adjudicator	109	97	0.37	60	66	0.55
Pulmonary embolism
Local Investigator	26	17	0.16	10	11	0.81
Central Adjudicator	26	19	0.29	11	13	0.70
Pneumonia
Local Investigator	89	100	0.44	74	50	0.030
Central Adjudicator	117	122	0.77	88	63	0.040
Other event
Local Investigator	210	220	0.65	140	115	0.11
Central Adjudicator	212	212	0.95	134	119	0.35

*p-values are from a chi-squared test between treatment groups

GTN = Glyceryl trinitrate